Respondents broadly supported clearer guidance on how evidence on health inequalities should be presented and how impacts are ...

For well over a decade, scientists, health leaders, and global organisations have sounded the alarm on antimicrobial ...

Connecting 80+ EHS experts in pharma and biopharma on the West coast, this year's meeting will address the challenges of ...

Despite a certain amount of upheaval at the FDA, the agency has continued to keep up with its scheduled approvals and clearances. At BIO 2025, editor-in-chief Jonah Comstock sat down with Mursla Bio ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

The deal for CARGO, which remains relatively well funded despite its troubles, comes with a contingent value right (CVR) that ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new 10-year plan for the NHS ...

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in ...

The Trump administration is preparing a new executive order that would seek thousands of layoffs at federal health agencies, including the FDA, according to the Wall Street Journal. Citing people ...

pharmaphorum is your source for news and analysis to stay on top of happenings in the world of pharma. Founded in 2009, pharmaphorum’s mission has always been to educate, inform, engage, and ...